CLOs on the Move

SleepImage

www.sleepimage.com

 
SleepImage Ring The SleepImage Rings stream data to the SleepImage Mobile App for upload, offering the highest level of comfort and convenience. SleepImage Mobile App The SleepImage Mobile App collects sleep data and  automatically uploads it in the mo...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Wildflower Court

Wildflower Court is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Wildflower Court is based in Juneau, AK. You can find more information on Wildflower Court at www.wildflowercourt.org

Aneurysm Outreach Inc

Aneurysm Outreach Inc is a Prairieville, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PreferredOne

At PreferredOne, our name says it all. You, our valued members, are our preferred ones. Everything we do is for one purpose - to make your experience the best it can be.   We offer individual health insurance, family medical plans and group health insurance to fit your needs and budget, plus wellness programs to help you stay healthy. We are known for outstanding customer service and for paying claims promptly, and our representatives are available to answer any questions you have about health care coverage.   PreferredOne has served our Minnesota and upper Midwest members for almost 30 years.

GroupOne Healthsource

GroupOne Healthsource is a Jefferson City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.